

References used in the **Anticipate the Season** Infographic Flashcard

1. CDC. RESP-NET. Respiratory Virus Hospitalization Surveillance Network (RESP-NET). Accessed July 15, 2026. <https://www.cdc.gov/resp-net/dashboard/index.html>
2. CDC. Chapter 17: Pneumococcal Disease. In: *Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book)*. Updated May 1, 2024. Accessed July 16, 2026. <https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-17-pneumococcal-disease.html>
3. CDC. COVID. Preliminary Estimates of COVID-19 Burden. February 6, 2026. Accessed July 15, 2026. <https://www.cdc.gov/covid/php/surveillance/burden-estimates.html>
4. CDC. RSV in adults. July 8, 2025. Accessed July 15, 2026. <https://www.cdc.gov/rsv/adults/index.html>
5. Havers FP, Whitaker M, Melgar M, et al. Burden of respiratory syncytial virus–associated hospitalizations in US adults, October 2016 to September 2023. *JAMA Netw Open*. 2024;7(11):e2444756.
6. Kapinos KA, Peters RM Jr, Murphy RE, Hohmann SF, Podichetty A, Greenberg RS. Inpatient costs of treating patients with COVID-19. *JAMA Netw Open*. 2024;7(1):e2350145.
7. Landi SN, Garofalo DC, Reimbaeva M, et al. Hospitalization following outpatient diagnosis of respiratory syncytial virus in adults. *JAMA Netw Open*. 2024;7(11):e2446010.
8. Mohanty S, Cossrow N, Yu KC, Ye G, White M, Gupta V. Clinical and economic burden of invasive pneumococcal disease and noninvasive all-cause pneumonia in hospitalized US adults: a multicenter analysis from 2015 to 2020. *Int J Infect Dis*. 2024;143:107023.
9. Averin A, Atwood M, Sato R, et al. Attributable cost of adult respiratory syncytial virus illness beyond the acute phase. *Open Forum Infect Dis*. 2024;11(3):ofae097.
10. Ramirez J, Furmanek S, Chandler TR, et al. Epidemiology of pneumococcal pneumonia in Louisville, Kentucky, and its estimated burden of disease in the United States. *Microorganisms*. 2023;11(11):2813.
11. National Foundation for Infectious Diseases (NFID). Call to Action: Strategies to Improve Adult Immunization in the US. September 9, 2024. Accessed July 15, 2026. <https://www.nfid.org/resource/call-to-action-strategies-to-improve-adult-immunization-in-the-us/>
12. CDC. COVID. Coronavirus Disease 2019 (COVID-19) Hospitalization Surveillance Network (COVID-NET). January 30, 2026. Accessed July 15, 2026. <https://www.cdc.gov/covid/php/covid-net/index.html>
13. Salah HM, Fudim M, O’Neil ST, Manna A, Chute CG, Caughey MC. Post-recovery COVID-19 and incident heart failure in the National COVID Cohort Collaborative (N3C) study. *Nat Commun*. 2022;13(1):4117.
14. Zhang V, Fisher M, Hou W, Zhang L, Duong TQ. Incidence of new-onset hypertension post-COVID-19: comparison with influenza. *Hypertension*. 2023;80(10):2135-2148.
15. Chourasia P, Goyal L, Kansal D, et al. Risk of new-onset diabetes mellitus as a post-COVID-19 condition and possible mechanisms: a scoping review. *J Clin Med*. 2023;12(3):1159.
16. Zhang J, Shu T, Zhu R, Yang F, Zhang B, Lai X. The long-term effect of COVID-19 disease severity on risk of diabetes incidence and the near 1-year follow-up outcomes among postdischarge patients in Wuhan. *J Clin Med*. 2022;11(11):3094.
17. Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. *Lancet Diabetes Endocrinol*. 2022;10(5):311-321.
18. Tseng HF, Sy LS, Ackerson B, Solano Z, Slezak J, Luo Y, Fischetti CA, Shinde V. Severe morbidity and short- and mid- to long-term mortality in older adults hospitalized with respiratory syncytial virus infection. *J Infect Dis*. 2020;222(8):1298-1310.
19. Ubamadu E, Betancur E, Gessner BD, et al. Respiratory syncytial virus sequelae among adults in high-income countries: a systematic literature review and meta-analysis. *Infect Dis Ther*. 2024;13(7):1399-1417.
20. Kruckow KL, Zhao K, Bowdish DME, Orihuela CJ. Acute organ injury and long-term sequelae of severe pneumococcal infections. *Pneumonia (Nathan)*. 2023;15(1):5.

21. Branche AR, Saiman L, Walsh EE, et al. Change in functional status associated with respiratory syncytial virus infection in hospitalized older adults. *Influenza Other Respir Viruses*. 2022;16(6):1151-1160.
22. Ramirez J, Hubble RA, Ali M, et al. Streptococcus pneumoniae serotype distribution among US adults hospitalized with community-acquired pneumonia, 2019–2020. *Open Forum Infect Dis*. 2024;12(1):ofae727.
23. Immunize.org. Using standing orders for administering vaccines: what you should know. May 2023. Accessed July 16, 2026. <https://www.immunize.org/wp-content/uploads/catg.d/p3066.pdf>
24. CDC. *Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book)*. Updated May 1, 2024. Accessed July 16, 2026. <https://www.cdc.gov/pinkbook/hcp/table-of-contents/index.html>
25. Heisler-MacKinnon JA, Queen T, Yi Kong W, et al. Identifying effective vaccine champions: findings from a national survey of primary care professionals. *Vaccine*. 2024;42(13):3148-3152.
26. CDC. Respiratory Illnesses. Respiratory Illness Season Toolkit. February 27, 2026. Accessed July 16, 2026. <https://www.cdc.gov/respiratory-viruses/php/toolkit/index.html>
27. CDC. COVID-19. COVID-19 treatment clinical care for outpatients. February 5, 2026. Accessed July 16, 2026. <https://www.cdc.gov/covid/hcp/clinical-care/outpatient-treatment.html>
28. CDC. Respiratory syncytial virus infection (RSV): symptoms and care of RSV. February 20, 2026. Accessed July 16, 2026. <https://www.cdc.gov/rsv/symptoms/index.html>
29. Maggi S, Launay O, Dawson R. Respiratory virus vaccines: pathways to recommendations and enhanced coverage for at-risk population. *Infect Dis Ther*. 2025;14(suppl 1):99-114.